Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price39.55 USD
Fair value38.81
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation39.55+0.0% to today ✓
2026-08-16Read Markdown44.73-11.6% to today ✓
2026-07-02Read Distribution37.46+5.6% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Vericel Corporation holds its Markdown at $39.55. The statistical read favours the sellers, held for 196 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 196 days
Price at the screen
$39.55
Valuation
82.40 trailing · 46.75 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.05
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
19.75%
Below 33%
Interest-bearing debt is just 19.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
12.58%
Below 33%
Cash held in interest-bearing accounts and securities is 12.6% of assets, under the one-third limit.
Pass
Receivables
37.86%
Below 49%
Money owed to the company is 37.9% of assets, under the 49% limit.
Pass
Revenue purity
2.54%
Below 5%
Only 2.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Vericel clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 1.9% above the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +49% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cell Patches Priced Well Beyond Their Reach
Picture a surgeon grafting living cells onto a burned patient or a torn cartilage in an athlete. Vericel supplies those therapies in North America and has lifted revenue 30 percent. Yet the business still clears only a 7 percent profit margin and a matching 7 percent return on equity, leaving little evidence of durable advantage.
We pass. At 54.7 times forward earnings the shares sit 21 percent above our fair value, and the market's strong buy chorus has already baked in flawless execution. An unknown moat in a field where competitors and regulators can shift quickly makes that premium look fragile rather than compelling.
Growth is real and the ethical screen clears, but the numbers show a company that must deliver far more than its current returns to justify today's price. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VCEL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (7 analysts) rates it strong buy, with a mean price target of $55.
2026-09-16Markdown$41.18-7.9%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (7 analysts) rates it strong buy, with a mean price target of $55.
2026-08-16Markdown · changed$44.73+19.4%Entry 4
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 19.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (7 analysts) rates it strong buy, with a mean price target of $55.
2026-07-18Distribution$37.46+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (7 analysts) rates it strong buy, with a mean price target of $55.
2026-07-03Distribution$37.46+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$37.46Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
